• Monitoring for recurrence, particularly patients with scarring due to previous Surgery or Radiotherapy


  • Suspected recurrence in treated Breast Cancer


  • High risk patients with family history of Breast Cancer who are unable to undergo breast MRI due to claustrophobia, poor renal function or metallic implants


  • Assessing response to Neoadjuvant Chemotherapy
    ​
  • Dense Breast Tissue - Secondary Screening

Dr. Carrie Hruska on MBI

Mayo Clinic

CLINICIANS

CLINICAL CHALLENGES

Pre-NAC                 3 - 5 Weeks               Completion

CLINICAL STUDIES

  • Indeterminate Mammogram and/or Ultrasound


  • Suspicious Mammographic Lesion (Secondary Diagnosis)


  • Symptomatic Patient with Negative Mammogram and/or Ultrasound

MBI Provides Greater Clinical Confidence

  • Predicting response to Neoadjuvant Chemotherapy

MBI is a valuable tool for Supplemental Screening in women with Dense Breasts


MBI’s High Sensitivity leads to the detection of almost 4 times more cancers than Mammography alone in women with Dense Breast Tissue

MBI’s High Specificity leads to fewer unnecessary (negative) biopsies compared to other Supplemental Screening modalities

MBI has been found to be more cost effective than other imaging modalities when used as an adjunct to Mammography in screening for women with Dense Breast Tissue

  • Imaging Patients with Breast Implants

The New Breast Exam That Nearly Quadruples Detection

Dr. Jay K. Harness & Dr. Michael O'Connor

CLINICAL INDICATIONS FOR MBI

Different Types of Tumours are Seen with Different Modalities

Responder




​​Non-Responder

 MBI with the GE Discovery NM750b:


  • Affords a 3-fold improvement in imaging Sensitivity compared to conventional Scintimammography


  • Is not affected by Dense Breast Tissue

​
 


JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts
Deborah J. Rhodes, Carrie B. Hruska, Amy Lynn Conners, Cindy L. Tortorelli, Robert W. Maxwell, Katie N. Jones, Alicia Y. Toledano and Michael K. O'Connor

Read More: http://www.ajronline.org/doi/abs/10.2214/AJR.14.13357


Diagnostic Workup and Costs of a Single Supplemental Molecular Breast Imaging Screen of Mammographically Dense Breasts
Carrie B. Hruska, Amy Lynn Conners, Katie N. Jones, Michael K. O'Connor, James P. Moriarty, Judy C. Boughey and Deborah J. Rhodes

Read More: http://www.ajronline.org/doi/abs/10.2214/AJR.14.13306


Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue
Robin B. Shermis, Keith D. Wilson, Malcolm T. Doyle, Tamara S. Martin, Dawn Merryman, Haris Kudrolli and R. James Brenner

Read More: http://www.ajronline.org/doi/abs/10.2214/AJR.15.15924


Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study
Carrie B. Hruska,Christopher G. Scott, Amy Lynn Conners, Dana H. Whaley, Deborah J. Rhodes, Rickey E. Carter, Michael K. O’Connor, Katie N. Hunt, Kathleen R. Brandt and Celine M. Vachon

Read more: https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-016-0704-6





  • Evaluating extent of disease (Surgical Planning)


  • Local Extent of Disease


  • Multi-focal or Multi-centric Disease


  • Contralateral Involvement











​

  • ​A reduction in T/B ratio of greater than 50% demonstrated the ability to differentiate responders from non-responders with an accuracy of 89.5% as early as 3 to 5 weeks after the initiation of NAC


  • Tumour size post-NAC from MBI correlated better with pathological tumour size than Mammography, Ultrasound, or clinical assessment